Navigation Links
Opexa Presents Tovaxin Research at Federation of Clinical,Immunology Societies Annual Meeting

Jim Williams, PhD, chief operating officer.

About T-cell Vaccination

For a T-cell vaccine to be effective, it should be able to induce T-cell cytotoxic and/or regulatory immune responses against the pathogenic T-cells. Studies of T-cell vaccine have indicated that T-cell vaccination with peripheral blood-derived autologous myelin-peptide selected T-cells in multiple sclerosis patients resulted in the in vivo induction of CD8+ cytotoxic T-cells and CD4+CD25+FoxP3 Tregs specific for T-cell vaccine. The induction of anti-idiotypic cytotoxic CD8+ effector T-cells and anti-ergotypic CD4+CD25+FoxP3 positive Tregs is believed to provide a therapeutically effective dual mechanism of protection to patients treated with Tovaxin(TM). The observed regulatory immune responses have been shown to collectively correlate with clinical improvement in treated patients.

About TERMS

The Tovaxin Phase IIb clinical study will include 150 patients in a multicenter, randomized, double blind, placebo-controlled trial designed primarily to evaluate the efficacy, safety and tolerability of the Tovaxin T Cell vaccination with clinically isolated syndrome (CIS) and relapsing-remitting MS (RR-MS) patients. A total of 100 patients will receive Tovaxin, while 50 will receive placebo. The study is designed as a two-arm, 52-week, parallel-group study, whereby patients will be given five subcutaneous injections at 0, 4, 8, 12 and 24 weeks. The analyses will be performed at the end of the 52-week study to assess the safety and efficacy of Tovaxin. The primary efficacy variable is the cumulative number of gadolinium-enhancing lesions on T1-weighted MRI scans summed over the Week 28, 36, 44, and 52 MRIs. The secondary efficacy variables are the cumulative number of new gadolinium-enhancing lesions at Weeks 28-52, the change in T2-weighted lesion volume, and the annualized relapse rate.

All patients who complete the trial will be eligible to participate in an optional o
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice
2. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
3. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin for Multiple Sclerosis
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
6. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
7. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
10. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
11. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
Post Your Comments:
(Date:7/28/2015)... (NYSE: EW ), the global leader in the ... net income for the quarter ended June 30, 2015 of ... income on a non-GAAP basis was $124.4 million, or ... share in the prior year period. In the year ... share, which included a $750 million payment to Edwards ...
(Date:7/28/2015)... 28, 2015   Regulus Therapeutics Inc . ( ... and development of innovative medicines targeting microRNAs, today announced ... the quarter ended June 30, 2015 on Tuesday, August ... Regulus will host a conference call and ... Eastern Daylight Time to discuss its second quarter 2015 ...
(Date:7/28/2015)... LOUIS, July 28, 2015  Express Scripts Holding Company ... income attributable to Express Scripts stockholders of $600.1 million, ... share, as detailed in Table 4, were $1.44 for ... is clear many companies across healthcare are validating the ... and Chief Executive Officer. "But, what matters most is ...
Breaking Medicine Technology:Edwards Lifesciences Reports Second Quarter Results 2Edwards Lifesciences Reports Second Quarter Results 3Edwards Lifesciences Reports Second Quarter Results 4Edwards Lifesciences Reports Second Quarter Results 5Edwards Lifesciences Reports Second Quarter Results 6Edwards Lifesciences Reports Second Quarter Results 7Edwards Lifesciences Reports Second Quarter Results 8Edwards Lifesciences Reports Second Quarter Results 9Edwards Lifesciences Reports Second Quarter Results 10Edwards Lifesciences Reports Second Quarter Results 11Edwards Lifesciences Reports Second Quarter Results 12Edwards Lifesciences Reports Second Quarter Results 13Edwards Lifesciences Reports Second Quarter Results 14Edwards Lifesciences Reports Second Quarter Results 15Edwards Lifesciences Reports Second Quarter Results 16Edwards Lifesciences Reports Second Quarter Results 17Edwards Lifesciences Reports Second Quarter Results 18Edwards Lifesciences Reports Second Quarter Results 19Edwards Lifesciences Reports Second Quarter Results 20Edwards Lifesciences Reports Second Quarter Results 21Edwards Lifesciences Reports Second Quarter Results 22Edwards Lifesciences Reports Second Quarter Results 23Regulus Announces Timing for Second Quarter 2015 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2015 Financial Results Webcast and Conference Call 3Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 2Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 3Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 4Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 5Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 6Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 7Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 8Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 9Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 10Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 11Express Scripts Announces 2nd Quarter Results; Increases 2015 Guidance Range 12
(Date:7/28/2015)... ... July 28, 2015 , ... World Patent ... and Found, a breakthrough technological invention. It is a wearable personal tracking ... electronic industry reached a record high of $211.3 billion in 2014," says Scott ...
(Date:7/28/2015)... NJ (PRWEB) , ... July 28, 2015 , ... Morristown ... in New Jersey, and one of the first five hospitals in the nation, to ... in three patients on July 23, and all are in good condition. , The ...
(Date:7/28/2015)... ... July 28, 2015 , ... DuPont ... visit to Ethiopia to learn more about the impact of U.S. collaborations with ... initiative focuses on accelerating agricultural development as an engine of broad-based economic growth ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... Women in ... Washington, D.C. technology community for over 20 years, has selected Lisa Dezzutti, CEO and ... upcoming year. , “I am excited to serve this organization that empowers women to ...
(Date:7/28/2015)... ... July 28, 2015 , ... OrthAlign, Inc., a ... ORTHALIGN PLUS® system, a palm-sized, single-use navigation device for Total Hip Arthroplasty (cup ... with practicality in a revolutionary way for Total Knee Arthroplasty surgeries and is ...
Breaking Medicine News(10 mins):Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 2Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 3Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 4Health News:Getting Back to Basic with Bluetooth Is What the World Patent Marketing Review Team and Lost and Found Are All About 5Health News:Morristown Medical Center First Hospital in New Jersey to Implant Newly Approved Heart Valve 2Health News:Morristown Medical Center First Hospital in New Jersey to Implant Newly Approved Heart Valve 3Health News:US President learns from DuPont Innovations in Food and Agriculture in Ethiopia 2Health News:US President learns from DuPont Innovations in Food and Agriculture in Ethiopia 3Health News:US President learns from DuPont Innovations in Food and Agriculture in Ethiopia 4Health News:Lisa Dezzutti Named President of Women in Technology (WIT) Board of Directors 2Health News:OrthAlign, Inc. Announces U.S. Commercial Launch of ORTHALIGN PLUS®, the most complete handheld navigation device for use in Total Hip Arthroplasty Surgery 2Health News:OrthAlign, Inc. Announces U.S. Commercial Launch of ORTHALIGN PLUS®, the most complete handheld navigation device for use in Total Hip Arthroplasty Surgery 3
... Behen HealthDay Reporter , WEDNESDAY, Sept. 22 ... arthritis (RA) may benefit patients with this chronic autoimmune ... therapy, researchers say. The oral medication, known as ... of drugs known as spleen tyrosine kinase (Syk) inhibitors, ...
... The American Society for Radiation Oncology (ASTRO) is pleased ... Recipients will receive their honors during ASTRO,s 52nd Annual ... 2010. ,"It is my pleasure to congratulate each ... this year," Anthony L. Zietman, M.D., ASTRO president and ...
... international study of patients with a devastating type of dementia ... evidence that career choice may influence where the disease takes ... led by Baycrest,s Rotman Research Institute in collaboration with the ... Francisco and several U.S. and European clinical sites. It appears ...
... HealthDay Reporter , TUESDAY, Sept. 21 (HealthDay News) -- ... 3-D movies, everyone seems to be oohing and ahhing over ... Well, almost everyone. "There will be at least one ... about? I didn,t see anything flying out at me., Or ...
... finds that college women with roommates who weigh more ... than women with slimmer roommates: half a pound versus ... freshman weight gain of 2.5-to-6 pounds---much less than the ... there are some good explanations for why it may ...
... PROVIDENCE, RI Damian Dupuy, MD, of Rhode Island ... from the American College of Radiology Imaging Network (ACRIN). ... on the use of radiofrequency ablation (RFA) to reduce ... the bone). The award recognizes a scientific paper published ...
Cached Medicine News:Health News:Novel Rheumatoid Arthritis Drug Shows Early Promise 2Health News:Novel Rheumatoid Arthritis Drug Shows Early Promise 3Health News:Novel Rheumatoid Arthritis Drug Shows Early Promise 4Health News:ASTRO announces 2010 Annual Meeting awards 2Health News:ASTRO announces 2010 Annual Meeting awards 3Health News:For sufferers of an early-onset dementia, career choice may determine location of disease in brain 2Health News:For sufferers of an early-onset dementia, career choice may determine location of disease in brain 3Health News:Vision Problems Can Rob Movie-Goers of 3-D 2Health News:Vision Problems Can Rob Movie-Goers of 3-D 3Health News:Freshman weight gain: Women with heavy roommates gain less 2Health News:Rhode Island Hospital physician receives national award for research 2
Gamma Glutamyl Transferase reagent is used for the quantitative determination of Gamma -GT in human serum....
For the quantitative kinetic determination of amylase activity, using manual or automated procedures, in human serum and urine....
For quantitative determination of amylase in human serum....
g-GT Liquid Reagent (Kinetic Method). Wavelength: 405 nm. Linear range: 0-200 U/mL. Prepare Working Reagent in the ratio of 5 parts R1 to 1 part of R2, (i.e., 50 mL R1 and 10 mL R2)....
Medicine Products: